Related Experiment Video
Updated: Jul 30, 2026
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Targeting SIRT3 to Ameliorate Diabetic Cardiomyopathy: Progress in Mechanistic Research and Prospects for Clinical
Yuting Lin1, Kun Yu1, Jinjian Guo1
1The Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Insights
Diabetic cardiomyopathy (DCM) is a serious complication of diabetes mellitus. Research highlights Sirtuin 3 (SIRT3) as a potential therapeutic target for improving cardiac function in DCM patients.
Area of Science:
- Cardiology
- Metabolic Diseases
- Mitochondrial Biology
Background:
- Diabetic cardiomyopathy (DCM) is a cardiac complication of diabetes mellitus (DM), characterized by structural and functional myocardial abnormalities.
- DCM develops insidiously and lacks effective treatments, even with glycemic control.
- Identifying novel therapeutic targets for DCM is a critical research focus.
Purpose of the Study:
- To investigate the role of Sirtuin 3 (SIRT3) in the pathogenesis of diabetic cardiomyopathy.
- To elucidate the mechanisms by which SIRT3 influences DCM.
- To explore strategies for improving DCM by modulating SIRT3 levels.
Main Methods:
- Review of existing literature on SIRT3 and its involvement in cardiovascular diseases, particularly DCM.
- Analysis of studies detailing the molecular mechanisms of SIRT3 in the context of diabetes-induced cardiac dysfunction.
- Synthesis of findings on interventions aimed at increasing SIRT3 levels for potential DCM treatment.
Main Results:
- Sirtuin 3 (SIRT3) exhibits protective effects against cardiovascular diseases.
- SIRT3 plays a significant role in mitigating the cardiac abnormalities associated with diabetic cardiomyopathy.
- Elevating SIRT3 levels presents a promising therapeutic avenue for managing DCM.
Conclusions:
- SIRT3 is a key regulator in the development and progression of diabetic cardiomyopathy.
- Targeting SIRT3 offers a potential strategy for the treatment and prevention of DCM.
- Further research into SIRT3 modulation could lead to novel therapeutic interventions for diabetic heart disease.
Abstract:
Diabetes mellitus (DM) is one of the most common chronic diseases worldwide, and diabetic cardiomyopathy (DCM) is one of the cardiovascular complications of DM, described as the development of abnormalities of myocardial structure/function associated with DM in the absence of coronary artery disease, hypertension, and valvular disease. The disease has an insidious onset and lacks effective treatment. Studies have shown that even with effective glycemic control, the progression of DCM cannot be prevented. Exploring the pathogenesis of DCM and identifying effective intervention targets is the focus and hotspot of current research. Silent message regulator 3 (Sirtuin3, SIRT3) is one of the members of the nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase family of sirtuins, and studies have confirmed that SIRT3 has a protective effect on cardiovascular disease and may become a new target for the treatment of cardiovascular diseases. Therefore, this paper emphasizes the role of SIRT3 in DCM, describes the mechanism of SIRT3 in DCM, and summarizes the methods to improve DCM by elevating the level of SIRT3, aiming to provide new perspectives for treating and delaying DCM.
